Equillium, Inc. · NASDAQ:EQ
Equillium — Merger or Acquisition (September 2022)
9 slides from Equillium's merger presentation, Sep 6, 2022
Slide 1: Equillium Acquisition of Metacrine, Inc.
Equillium Acquisition of Metacrine, Inc. September 7, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). Statements contained in this presentation that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
Slide 3: Additional Information and Where to Find it
Additional Information Additional Information and Where to Find it This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed merger or otherwise. No offer of securities shall be
Slide 4: Expected to add an estimated $33,000,000 in cash at closing
Expected to add an estimated $33,000,000 in cash at closing Equillium Acquisition of Metacrine, Inc. Stockholder vote required by both EQ & MTCR All stock transaction EQ share issuance based on MTCR net cash at closing plus a 25% premium, divided by EQ share price using 10-day VWAP ten trading days
Slide 5: Expanded and Diversified Pipeline
Expanded and Diversified Pipeline Drug Indication & Delivery Discovery & Pre-Clinical Pre-Clinical Phase 1 Phase 2 Phase 3 Status & Designations EQ001 Itolizumab anti-CD6 acute graft-versus-host disease intravenous Pivotal study to support BLA filing FDA Fast Track and Orphan Drug Designations syste
Slide 6: Corporate
¢ _ . eQuillium — 4 Corporate
Slide 7: Expected to add $33 million in cash at closing and extend operating runway into 2024
Expected to add $33 million in cash at closing and extend operating runway into 2024 Adds to achievable catalysts with current runway No additional FTEs and maintain sole discretion over the advancement of Metacrine programs No increase to R&D opex All-Stock Transaction EQ share issuance based on MT
Slide 8: Catalysts & Milestones
Catalysts & Milestones Financed through multiple operational milestones and data catalysts Catalysts & Milestones Expected Timing EQUALISE Interim data from Phase 1b EQUALISE study - Type B patients (lupus nephritis) Mid 2022 Topline data from Phase 1b EQUALISE study - Type B patients (lupus nephrit
Slide 9: Thank you
Thank you www.equilliumbio.com